Changes in matrix metalloproteinase-9 levels during progression of atrial fibrillation

• Published in: Journal of international medical research 2014-02, Vol.42 (1), p.224-230
• Main Authors: Li, Mingjiang, Yang, Guokang, Xie, Bin, Babu, Kamesh, Huang, Congxin
• Format: Article
• Language: English
• Subjects: Adult; Aged; Atrial Fibrillation - enzymology; Biological and medical sciences; Cardiac dysrhythmias; Cardiology. Vascular system; Case-Control Studies; Disease Progression; Enzyme-Linked Immunosorbent Assay; Female; Heart; Humans; Male; Matrix Metalloproteinase 9 - metabolism; Medical sciences; Middle Aged; Pharmacology. Drug treatments; Prospective Studies
• ISSN: 0300-0605; 1473-2300
• DOI: 10.1177/0300060513488514

Objectives: To observe levels of matrix metalloproteinase (MMP)-9 and evaluate their significance in various stages of idiopathic atrial fibrillation (AF). Methods: Patients with idiopathic AF were recruited into this prospective study and classified into one of three groups according to stage of disease progression: paroxysmal AF; persistent AF; permanent AF. Healthy individuals were enrolled as control subjects. Serum levels of MMP-9 in all four groups were determined using a double-antibody sandwich enzyme-linked immunosorbent assay. Results: Each AF group included 25 patients; 40 healthy individuals were included as controls. MMP-9 levels in the three AF groups were significantly higher than in the control group: 168.72 ± 25.970, 201.36 ± 31.26 and 253.20 ± 22.99 ng/ml for the paroxysmal, persistent and permanent AF groups respectively, versus 76.80 ± 14.90 ng/ml for the control group. MMP-9 levels increased with idiopathic AF disease progression (P